[ad_1] Covid-19 vaccination centre at a Chemist shop on 28th April 2023 in London, United Kingdom. Mike Kemp | In Pictures | Getty Images LONDON — England on Monday began its winter Covid-19 and flu vaccination campaign ahead of schedule as it monitors a new variant and seeks to avoid another “twindemic” straining the health-care…
[ad_1] Merck & Co. Inc.’s Januvia brand medication, used to treat Type 2 diabetes. Daniel Acker | Bloomberg | Getty Images Medicare is poised to directly negotiate drug prices with the pharmaceutical industry this fall for the first time in the program’s nearly six-decade history. The Centers for Medicare and Medicaid Services will unveil, no…
[ad_1] Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims New York-based Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. related investing news “Upon information and…
[ad_1] Budrul Chukrut | Lightrocket | Getty Images GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company’s new RSV vaccine to start off slower than it did for its blockbuster shingles shot. But she is confident that the new vaccine will drive future sales. “I think the uptake on this we…
[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images The Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose of RSV vaccines from Pfizer and GSK after consulting their doctors. Outgoing CDC Director Rochelle Walensky signed off on the recommendation, which an advisory…
[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis. A CDC medical officer presented the…
[ad_1] A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022. Xinhua News Agency | Getty Images An advisory committee to the Centers for Disease Control and Prevention on Wednesday recommended that adults ages 60 and above, after consulting their…
[ad_1] Pfizer‘s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer’s clinical trial on more than 34,000 older adults over two RSV seasons. The latest data is specifically on…
[ad_1] Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images GlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory syncytial virus, or RSV, remained effective across two seasons of the disease. A single dose of the shot was 67.2% effective in preventing lower respiratory tract…
[ad_1] Luis Alvarez | Digitalvision | Getty Images The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes thousands of seniors every year. Pfizer, in a statement Wednesday, said it expects to have supply…
